Choose Your Country or Region

Flavopiridol (L86-8275)

Name: Flavopiridol (L86-8275)
Brand: Selleck Chemicals
SKU: S1230
Rating: 5 (99 reviews)

Catalog No.S1230 Synonyms: NSC 649890 HCl, HMR-1275, Alvocidib

For research use only.

Flavopiridol (L86-8275, Alvocidib, NSC 649890, HMR-1275) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4, CDK6, and CDK9 with IC50 values in the 20-100 nM range. It is more selective for CDK1, 2, 4, 6, 9 versus CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol induces autophagy and ER stress. Flavopiridol blocks HIV-1 replication. Phase 1/2.

Flavopiridol (L86-8275) Chemical Structure

CAS No. 146426-40-6

Selleck's Flavopiridol (L86-8275) has been cited by 99 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Related Compound Libraries

Other CDK Products

SU9516^New

SU 9516 is a 3-substituted indolinone CDK inhibitor with IC50 of 22 nM, 40 nM, and 200 nM for CDK2, CDK1, and CDK4, respectively.
Ro-3306^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases. RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis.
Purvalanol A^New

Purvalanol A is a potent, and cell-permeable CDK inhibitor with IC50 of 4 nM, 70 nM, 35 nM, and 850 nM for cdc2-cyclin B, cdk2-cyclin A, cdk2-cyclin E, and cdk4-cyclin D1, respectively. Purvalanol A induces endoplasmic reticulum stress-mediated apoptosis and autophagy.
Palbociclib (PD-0332991) HCl

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Palbociclib (PD0332991) Isethionate

Palbociclib (PD0332991) Isethionate is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
Dinaciclib (SCH727965)

Dinaciclib (SCH727965, PS-095760) is a novel and potent CDK inhibitor for CDK2, CDK5, CDK1 and CDK9 with IC50 of 1 nM, 1 nM, 3 nM and 4 nM in cell-free assays, respectively. It also blocks thymidine (dThd) DNA incorporation. Dinaciclib induces apoptosis through the activation of caspases 8 and 9. Phase 3.
Flavopiridol (L86-8275) HCl

Flavopiridol HCl (L86-8275, NSC 649890, Alvocidib, HMR-1275, DSP-2033) competes with ATP to inhibit CDKs including CDK1, CDK2, CDK4 and CDK6 with IC50 of ~ 40 nM in cell-free assays. It is 7.5-fold more selective for CDK1/2/4/6 than CDK7. Flavopiridol is initially found to inhibit EGFR and PKA. Flavopiridol HCl induces autophagy and ER stress. Flavopiridol HCl blocks HIV-1 replication. Phase 1/2.
Roscovitine (CYC202)

Roscovitine (CYC202, Seliciclib, R-roscovitine) is a potent and selective CDK inhibitor for Cdc2, CDK2 and CDK5 with IC50 of 0.65 μM, 0.7 μM and 0.16 μM in cell-free assays. It shows little effect on CDK4/6. Phase 2.
Abemaciclib mesylate (LY2835219)

Abemaciclib (LY2835219) is a potent and selective inhibitor of CDK4 and CDK6 with IC50 of 2 nM and 10 nM in cell-free assays, respectively. Phase 3.
Ribociclib (LEE011)

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Download Inhibitor Catalog

CDK Signaling Pathway Map

Biological Activity

Description

Features

First CDK inhibitor to be used in human clinical trials.

Targets

CDK9 ^[8] (Cell-free assay)	CDK1 ^[8] (Cell-free assay)	CDK4 ^[9] (Cell-free assay)	CDK2 ^[8] (Cell-free assay)	CDK6 ^[9] (Cell-free assay)	Click to View More Targets
20 nM	30 nM	20-40 nM	40 nM	60 nM	Click to View More Targets

In vitro

Flavopiridol displays less activity against unrelated kinases such as MAP, PAK, PKC, and EGFR with IC50 of >14 μM. Flavopiridol significantly inhibits the colony growth of HCT116, A2780, PC3, and Mia PaCa-2 cells with IC50 of 13 nM, 15 nM, 10 nM and 36 nM, respecitively. ^[1] Flavopiridol also potently inhibits the activity of Glycogen synthase kinase-3 (GSK-3) with an IC50 of 280 nm. ^[2] Compared with other CDKs, Flavopiridol inhibits the activity of CDK7 less potently with IC50 of 875 nM. Flavopiridol (0.5 μM) inhibits both pSer807/811 Rb and pThr199 NPM, whereas mild changes are observed at pThr821 Rb. Flavopiridol also decreases the overall RNA polymerase II level, as well as the phosphorylation of RNA polymerase II on the CTD repeats at Ser2 Ser5. ^[3] As a broad spectrum CDK inhibitor, Flavopiridol can inhibit cell cycle progression in either G1 or G2. Flavopiridol (0.3 μM) induces G1 arrest in either MCF-7 or MDA-MB-468 cells by inhibition of the CDK4 or CDK2 kinase activity. ^[4] Flavopiridol exhibits potent cytotoxicity against a wide variety of tumor cell lines with IC50 values ranging form 16 nM for LNCAP to 130 nM for K562. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

MCF-7 tumor cell	NV\yV2NQWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NYTuVJlSUW6qaXLpeIlwdiCxZjDNR2YuPyC2dX3vdkBk\WyuIIDyc4xq\mW{YYTpc44>	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODh2M{KxNUc,OTB6NEOyNVE9N2F-
PC3 cell	NWD2cpg6TnWwY4Tpc44h[XO\|YYm=			Mn3uTY5pcWKrdHnvckBw\iCSQ{OgZ4VtdCClbH;uc4dmdmmlIHHzd4F6NCCLQ{WwQVExKM7:TR?=	M4TtUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N\|YxQTxxYU6=
HCT116 cell	M4OzeGZ2dmO2aX;uJIF{e2G7			M4DKTGlvcGmkaYTpc44hd2ZiSFPUNVE3KGOnbHygZ4xwdm:pZX7pZ{Bie3OjeTygTWM2OD1zMzFOwG0>	M4\MN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzME[zOlA6Lz5zMUC2N\|YxQTxxYU6=
A2780 cell	MV7GeY5kfGmxbjDhd5NigQ>?			M2f5c2lvcGmkaYTpc44hd2ZiQUK3PFAh[2WubDDjcI9vd2enbnnjJIF{e2G778{MJGlEPTB;MUWg{txO	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
Mia PaCa-2 cell	NGO3boJHfW6ldHnvckBie3OjeR?=			MVjJcohq[mm2aX;uJI9nKE2rYTDQZWNiNTJiY3XscEBkdG:wb3flcolkKGG\|c3H5MEBKSzVyPUO2JO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB4M{[wPUc,OTFyNkO2NFk9N2F-
LNCaP human prostate carcinoma cell	MXPQdo9tcW[ncnH0bY9vKGG\|c3H5			MUnJcohq[mm2aX;uJI9nKEyQQ3HQJIh2dWGwIIDyc5N1[XSnIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
HCT116/VP35 human colon carcinoma cell	MUfQdo9tcW[ncnH0bY9vKGG\|c3H5			NV7UOGZKUW6qaXLpeIlwdiCxZjDIR3QyOTZxVmCzOUBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTF5IH7N	NWG4U3ZWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
HCT116 human colon carcinoma cell	M1\NSXBzd2yrZnXyZZRqd25iYYPzZZk>			MWnJcohq[mm2aX;uJI9nKEiFVEGxOkBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTF6IH7N	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
HCT116/VM46 human colon carcinoma cell	M1vFNHBzd2yrZnXyZZRqd25iYYPzZZk>			MkX0TY5pcWKrdHnvckBw\iCKQ2SxNVYwXk12NjDoeY1idiClb3zvckBk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVIyKG6P	MlnZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780/DDP-R human ovarian carcinoma cell	M3PER3Bzd2yrZnXyZZRqd25iYYPzZZk>			M3y5TmlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWKgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTN6IH7N	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
ABAE human fibroblast cell	NXu3d254WHKxbHnm[ZJifGmxbjDhd5NigQ>?			MkHjTY5pcWKrdHnvckBw\iCDQlHFJIh2dWGwIH\pZpJw[myjc4SgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUS1JI5O	NEX2[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
HL60 human leukemia cell	NGflUGlRem:uaX\ldoF1cW:wIHHzd4F6			MkfpTY5pcWKrdHnvckBw\iCKTE[wJIh2dWGwIHzleYtmdWmjIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD12NjDuUS=>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
Hs 27 human fibroblast cell	NGrSVIhRem:uaX\ldoF1cW:wIHHzd4F6			M1XuW2lvcGmkaYTpc44hd2ZiSIOgNlchcHWvYX6g[oljem:kbHHzeEBk\WyuIIDyc4xq\mW{YYTpc44tKEmFNUC9OVEhdk1?	MknvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
CCRF-CEM human leukemia cell	Ml;lVJJwdGmoZYLheIlwdiCjc4PhfS=>			NVjkbo1bUW6qaXLpeIlwdiCxZjDDR3JHNUOHTTDoeY1idiCuZYXr[Y1q[SClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PTJibl2=	M3u2SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
OVCAR-3 human ovarian carcinoma cell	M2DoTnBzd2yrZnXyZZRqd25iYYPzZZk>			MXXJcohq[mm2aX;uJI9nKE:YQ1HSMVMhcHWvYX6gc5ZiemmjbjDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUW0JI5O	NWrjVHdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
A2780/DDP-S human ovarian carcinoma cell	M4q0dHBzd2yrZnXyZZRqd25iYYPzZZk>			M1vM[GlvcGmkaYTpc44hd2ZiQUK3PFAwTESSLWOgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTV4IH7N	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-S human ovarian carcinoma cell	M3PQWXBzd2yrZnXyZZRqd25iYYPzZZk>			NXe4NZFlUW6qaXLpeIlwdiCxZjDBNlc5OC:WQWitV{BpfW2jbjDveoFzcWGwIHPhdoNqdm:vYTDj[YxtKHC{b3zp[oVz[XSrb36sJGlEPTB;NkWgcm0>	NEeyPWk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
LS174T human colon carcinoma cell	NGm5b2VRem:uaX\ldoF1cW:wIHHzd4F6			MYLJcohq[mm2aX;uJI9nKEyVMUe0WEBpfW2jbjDjc4xwdiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTZ3IH7N	M{XCS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
MCF-7 human breast carcinoma cell	NIC0U\|BRem:uaX\ldoF1cW:wIHHzd4F6			MULJcohq[mm2aX;uJI9nKE2FRj23JIh2dWGwIHLy[YF{fCClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTZ4IH7N	M17sTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
PC3 human prostate carcinoma cell	MWXQdo9tcW[ncnH0bY9vKGG\|c3H5			MWDJcohq[mm2aX;uJI9nKFCFMzDoeY1idiCycn;zeIF1\SClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTZ4IH7N	M4PPc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
MLF mouse lung fibroblast cell	MV3Qdo9tcW[ncnH0bY9vKGG\|c3H5			M3XwUmlvcGmkaYTpc44hd2ZiTVzGJI1wfXOnIHz1coch\mmkcn;icIF{fCClZXzsJJBzd2yrZnXyZZRqd25uIFnDOVA:PzJibl2=	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
LX-1 human lung carcinoma	MXrQdo9tcW[ncnH0bY9vKGG\|c3H5			NVXRPVRsUW6qaXLpeIlwdiCxZjDMXE0yKGi3bXHuJIx2dmdiY3HyZ4lvd22jIIDyc4xq\mW{YYTpc44tKEmFNUC9O\|Uhdk1?	NGr4d5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A431 human squamous cell	NW[3OlVzWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NGPVZ3JKdmirYnn0bY9vKG:oIFG0N\|EhcHWvYX6gd5F2[W2xdYOgZ4VtdCClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTd3IH7N	M4DkR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
SKBR-3 human breast carcinoma cell	NGWxdWRRem:uaX\ldoF1cW:wIHHzd4F6			M334OWlvcGmkaYTpc44hd2ZiU1vCVk0{KGi3bXHuJIJz\WG\|dDDjZZJkcW6xbXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUe3JI5O	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780/TAX-R human ovarian carcinoma cell	NVHmV2ZoWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M4DwZmlvcGmkaYTpc44hd2ZiQUK3PFAwXEG[LWKgbJVu[W5ib4\hdolidiClYYLjbY5wdWFiY3XscEBxem:uaX\ldoF1cW:wLDDJR\|UxRTd6IH7N	M3nndVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
M109 mouse lung carcinoma cell	MXLQdo9tcW[ncnH0bY9vKGG\|c3H5			MXfJcohq[mm2aX;uJI9nKE1zMEmgcY92e2VibIXu[{Bk[XKlaX7vcYEh[2WubDDwdo9tcW[ncnH0bY9vNCCLQ{WwQVgxKG6P	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
CACO-2 human colon carcinoma cell	Mn\HVJJwdGmoZYLheIlwdiCjc4PhfS=>			MmXBTY5pcWKrdHnvckBw\iCFQVPPMVIhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD16NjDuUS=>	Ml\zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A549 human lung carcinoma cell	M3\6dnBzd2yrZnXyZZRqd25iYYPzZZk>			NWTNRVNZUW6qaXLpeIlwdiCxZjDBOVQ6KGi3bXHuJIx2dmdiY3HyZ4lvd22jIHPlcIwheHKxbHnm[ZJifGmxbjygTWM2OD17NjDuUS=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
MIP human colon carcinoma cell	MlnUSpVv[3Srb36gZZN{[Xl?			NVvqXW91UW6qaXLpeIlwdiCxZjDNTXAhcHWvYX6gZ49td25iY3HyZ4lvd22jIHPlcIwhdGmwZTygTWM2OD1yLkGyJO69VQ>?	NGjD[o89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
K562 human leukemia cell	NUfB[VNFWHKxbHnm[ZJifGmxbjDhd5NigQ>?			NH2zUWFKdmirYnn0bY9vKG:oIFu1OlIhcHWvYX6gcIV2c2WvaXGgZ4VtdCCycn;sbYZmemG2aX;uMEBKSzVyPUCuNVMh\|ryP	NVrNToZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUKxPVA{OTNpPkGyNVkxOzF\|PD;hQi=>
human A2780 cell line	NFnUb\|FRem:uaX\ldoF1cW:wIHHzd4F6		NXLQ[\|BRPzJiaB?=	MWPBcpRqeHKxbHnm[ZJifGm4ZTDl[oZm[3RiYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxtKGyrbnWge4F{KGSndHXycYlv\WRiaX6gZUB4cG:uZTDj[YxtKDd{IHjyJIN6fG:2b4jpZ4l1gSCjc4PhfUwhUUN3ME23NUBvVQ>?	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTB{N{i2N{c,OTVyMke4OlM9N2F-
human ovarian (A2780) cancer cell	M{LDc2N6fG:2b4jpZ:Kh[XO\|YYm=			MY\DfZRwfG:6aXOg[YZn\WO2IH;uJIh2dWGwIH;2ZZJq[W5iKFGyO\|gxMSClYX7j[ZIh[2WubDDsbY5mNCCLQ{WwQVcyKG6P	NEj5SVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUGyOVk4OSd-MUWxNlU6PzF:L3G+
ID8 cells	M4\3XXBzd2yrZnXyZZRqd25iYYPzZZk>			NHX5UI5CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGlFQCClZXzsd{whUUN3ME23JI5O	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF{M{iyNUc,OTdzMkO4NlE9N2F-
MCF7 cells	NHnpUIFRem:uaX\ldoF1cW:wIHHzd4F6			MXvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IF3DSlch[2WubIOsJGlEPTB;Mk[gcm0>	NITQUI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{GyN\|gzOSd-MUexNlM5OjF:L3G+
Sf9 cells	Mmf6SpVv[3Srb36gZZN{[Xl?			NGnEN\|NKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIN6[2yrbjDBM2NFUzJiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{whUUN3ME2xNkBvVQ>?	NI\QOoE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mwOFM3Pid-MUe5NFQ{PjZ:L3G+
human A2780 cells	Mkf5SpVv[3Srb36gZZN{[Xl?			NVjLdVVlUW6qaXLpeIlwdiCxZjDj[IsudWWmaXH0[YQhVlCPIIDoc5NxcG:{eXzheIlwdiCjdDD0bJIyQTliaX6gbJVu[W5iQUK3PFAh[2WubIO=	NHuzOFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
human A2780 cells	MWTGeY5kfGmxbjDhd5NigQ>?		M3jFO\|I1KGh?	M13pSGlvcGmkaYTpc44hd2ZiY3TrMY1m\GmjdHXkJHJjKHCqb4PwbI9zgWyjdHnvckBifCC2aIK4NlEhcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYX\0[ZIhOjRiaILz	MnzvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2Nkm4NFkoRjF6NE[5PFA6RC:jPh?=
human NCI60 cells	Ml\SVJJwdGmoZYLheIlwdiCjc4PhfS=>		NHHEZpQ4OiCq	MVvBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FSU[wJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSC\|dXzmc5Jpd2SjbXnu[UBDKGG\|c3H5MEBIUTVyPUe0Mlchdk1?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTB6MEewN{c,OjFyOEC3NFM9N2F-
human NCI60 cells	M3rJb3Bzd2yrZnXyZZRqd25iYYPzZZk>		NELhT404OiCq	M4DleGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJOlAh[2WubIOgZZN{\XO\|ZXSgZZMhdGW2aHHsJIVn\mWldDDh[pRmeiB5MjDodpMh[nlic4Xs[o9zcG:mYX3pcoUhSiCjc4PhfUwhVEN3ME2wMlkxPCEQvF2=	NX\aN2RMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPFA4ODNpPkKxNFgxPzB\|PD;hQi=>
human A2780 cells	MmfvR5l1d3SxeHnjxsBie3OjeR?=		MXiyOEBp	MmDoR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3ME2yN{BvVQ>?	M{HqNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
human MRC5 cells	NGjG[5REgXSxdH;4bYPDqGG\|c3H5		M1:5bVczKGh?	MlPZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXJEPSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBIUTVyPUK4JI5O	NFvJe\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
human A2780 cells	M1n5T2N6fG:2b4jpZ:Kh[XO\|YYm=		MVe3NkBp	MnnaR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3ME2yPUBvVQ>?	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN\|MEG3Olc9N2F-
human A2780 cells	MX3DfZRwfG:6aXRCpIF{e2G7		MUC0PEBp	MkDuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhT0l3ME2zNUBvVQ>?	M{jVRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
human MRC5 cells	MWjDfZRwfG:6aXRCpIF{e2G7		NXz3Z4FHPDhiaB?=	MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNVmM2KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTB;M{mgcm0>	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzNyMUe2O{c,OjN\|MEG3Olc9N2F-
human MRC5 cells	MVnDfZRwfG:6aXRCpIF{e2G7		Mm\qNlQhcA>?	NHnUdFNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOWkN3IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEeLNUC9OFkhdk1?	MkLTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3OlcoRjJ\|M{CxO\|Y4RC:jPh?=
human HMEC1 cells	MVLDfZRwfG:6aXRCpIF{e2G7		MVOyOEBp	MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUWVEOSClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBIUTVyPU[xJI5O	MofDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN\|MEG3OlcoRjJ\|M{CxO\|Y4RC:jPh?=
human HMEC1 cells	NVPwV5hoS3m2b4TvfIlkyqCjc4PhfS=>		NWDnUGxzPDhiaB?=	M33yN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhOTUNzIHPlcIx{KGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEeLNUC9OlIhdk1?	NVnhenZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzNFE4PjdpPkKzN\|AyPzZ5PD;hQi=>
human HMEC1 cells	NGHkWo9EgXSxdH;4bYPDqGG\|c3H5		M1zBNlczKGh?	Mo\nR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTG1GSzFiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhT0l3ME22OkBvVQ>?	M{PJN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	NWrmeYR4TnWwY4Tpc44h[XO\|YYm=	M2fVblM{OCCwTR?=	NXnHW2lSOjRiaIK=	NV3mcoI4WGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckB{[i2JMTDh[pRmeiB{NDDodkBzKGG2IEOzNEBvVSBqSVO1NEktKEOnbHygZ5lkdGViPTCwMlAxOSEQvF2u	MoPuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	NH3P[mRCeG:ydH;zbZMh[XO\|YYm=	M1PkdVM{OCCwTR?=	MX[yOEBpeg>?	MWjBdI9xfG:2aXOgRVI4QDBiY3XscJMh[W[2ZYKgNlQhcHJicjDheEA{OzBibl2gLGlEPTBrLDDD[YxtKGO7Y3zlJF0hOC5yMEGg{txONg>?	M2GwUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
A2780	M1XvR2Z2dmO2aX;uJIF{e2G7	MW[yPVgxKG6P	M{XqTlI1KGi{	MnX3VIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDzeYIuTzFiYX\0[ZIhOjRiaIKgdkBifCB{OUiwJI5OKCiLQ{mwLUwhS2WubDDjfYNt\SB;IECuNFAzKM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	MXzBdI9xfG:\|aYOgZZN{[Xl?	Mni1Nlk5OCCwTR?=	MXiyOEBpeg>?	NX;TSppySXCxcITveIlkKEF{N{iwJINmdGy\|IHHmeIVzKDJ2IHjyJJIh[XRiMkm4NEBvVSBqSVO5NEktKEOnbHygZ5lkdGViPTCwMlAxQSEQvF2u	MmC4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	NXziRY1DTnWwY4Tpc44h[XO\|YYm=	MWiyPVgxKG6P	NULIbJhVOjRiaIK=	NXLPUllbWGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckBUNXCqYYPlJIFnfGW{IEK0JIhzKHJiYYSgNlk5OCCwTTCoTWM6OCluIFPlcIwh[3mlbHWgQUAxNjBzMjFOwG0v	MoL0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJzOUCzNVMoRjF{MUmwN\|E{RC:jPh?=
A2780	MYTGeY5kfGmxbjDhd5NigQ>?	M1rvPFM{OCCwTR?=	Mlv1NlQhcHJ?	MnvsVIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDTMZBp[XOnIHHmeIVzKDJ2IHjyJJIh[XRiM{OwJI5OKCiLQ{WwLUwhS2WubDDjfYNt\SB;IECuNFE3KM7:TT6=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	NGroV5ZHfW6ldHnvckBie3OjeR?=	Mn3XN\|MxKG6P	MkTNNlQhcHJ?	MYHQ[ZJk\W62YXflJGEzPzhyIHPlcIx{KGmwIFeyM20h[W[2ZYKgNlQhcHJicjDheEA{OzBibl2gLGlEPTBrLDDD[YxtKGO7Y3zlJF0hOC5yMkOg{txONg>?	M4S1cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{MUmwN\|E{Lz5zMkG5NFMyOzxxYU6=
A2780	MmHnSpVv[3Srb36gZZN{[Xl?	NHPpOW4zQThyIH7N	MYSyOEBpeg>?	M2\uPHBmemOnboTh[4UhSTJ5OECgZ4VtdHNiaX6gS\|IwVSCjZoTldkAzPCCqcjDyJIF1KDJ7OECgcm0hMEmFOUCpMEBE\WyuIHP5Z4xmKD1iMD6wNlUh\|ryPLh?=	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	MY\GeY5kfGmxbjDhd5NigQ>?	M2XlRVM{OCCwTR?=	NULSc5A5OjRiaIK=	NWLyOoxiWGW{Y3XueIFo\SCDMke4NEBk\WyuczDpckBIOSCjZoTldkAzPCCqcjDyJIF1KDN\|MDDuUUApUUN3MDmsJGNmdGxiY4njcIUhRSByLkC2JO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjF7MEOxN{c,OTJzOUCzNVM9N2F-
A2780	MYPGeY5kfGmxbjDhd5NigQ>?	NHHYUGMzQThyIH7N	NXLnbIpCOjRiaIK=	MoiyVIVz[2WwdHHn[UBCOjd6MDDj[YxteyCrbjDHNUBi\nSncjCyOEBpeiC{IHH0JFI6QDBibl2gLGlEQTBrLDDD[YxtKGO7Y3zlJF0hOC5yNkGg{txONg>?	NF3tfIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMkG5NFMyOyd-MUKxPVA{OTN:L3G+
A2780	MnnaSpVv[3Srb36gZZN{[Xl?		NX7O[ZBVOjRiaILz	NIC3emtKdmirYnn0bY9vKG:oIHPkb{1u\WSrYYTl[EBT[iCyaH;zdIhwenmuYYTpc44h[XRic3XyPFA4NzhzMTDpckBpfW2jbjDBNlc5OCClZXzsd{Bi\nSncjCyOEBpenN?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
A2780	MWLGeY5kfGmxbjDhd5NigQ>?		MofCNlQhcHK\|	MUHJcohq[mm2aX;uJI9nKGOma{mtcYVlcWG2ZXSgVm5CKHCxbEKgR3RFKHCqb4PwbI9zgWyjdHnvckBifCC\|ZYKyJIlvKGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{cx?=	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR4OUiwPUc,OTh2Nkm4NFk9N2F-
A2780	MW\GeY5kfGmxbjDhd5NigQ>?		MVOyOEBpenN?	MVfJcohq[mm2aX;uJI9nKGOma{etcYVlcWG2ZXSgVm5CKHCxbEKgR3RFKHCqb4PwbI9zgWyjdHnvckBifCC\|ZYK1JIlvKGi3bXHuJGEzPzhyIHPlcIx{KGGodHXyJFI1KGi{cx?=	NHPwcVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES2PVgxQSd-MUi0Olk5ODl:L3G+
A2780	NYLac21qSXCxcITvd4l{KGG\|c3H5		NEHPT4czPCCqcoO=	M{Oycmlv\HWldHnvckBw\iCjcH;weI9{cXNiaX6gbJVu[W5iQUK3PFAh[2WubIOgZZN{\XO\|ZXSgZZMh[XCyZXHyZY5k\SCxZjDNZ4wyKHC{b4TlbY4hdGW4ZXygZYZ1\XJiMkSgbJJ{	NVrkOWJGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0Olk5ODlpPkG4OFY6QDB7PD;hQi=>
DR-U2OS-GFP	MXXGeY5kfGmxbjDhd5NigQ>?	NIjTcG0xNjFidV2=	MWK1OkBpenN?	NH71bXNT\WS3Y4Tpc44hd2ZiaH;tc4xw\2:3czDy[YNwdWKrbnH0bY9vKGmwIHj1cYFvKESULWWyU3MuT0[SIHPlcIx{KGW6cILld5NqdmdiST3TZ4VKKG63Y3zlZZNmKGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDv[kBTSUR3MTDs[ZZmdCCjdDCwMlEhfU1iYX\0[ZIhPTZiaILzJIJ6KGmvbYXuc4Jtd3S2aX7n	MofOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2MUe0NVcoRjJzNEG3OFE4RC:jPh?=
A2780	MVjGeY5kfGmxbjDhd5NigQ>?		M1TxS\|I1KGi{cx?=	M3fuZmlvcGmkaYTpc44hd2ZiQ1TLPUBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4YhWk6DUFnJJGNVTCCyaH;zdIhwenmuYYTpc44h[XRiU3XyNkBifCCJSUWwJINwdmOnboTyZZRqd25iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	M4H0bVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	MlfYR4VtdCCleXPs[UBie3OjeR?=		MorINlQhcHK\|	NEfwR29E\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBCOjd6MDDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{KvUUBxcGG\|ZTDheEBt\XO\|IIToZY4hT0l3MDDh[pRmeiB{NDDodpMh[nliZnzve{BkgXSxbXX0dolkKGGwYXz5d4l{	NF\ucGE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
A2780	NW[zW4IzTnWwY4Tpc44h[XO\|YYm=		NH\YZokzPCCqcoO=	NGLWc3NKdmirYnn0bY9vKG:oIFPET\|khcW5iaIXtZY4hSTJ5OECgZ4VtdHNiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gUWNNOSCjdDDHTVUxKHSxIEXYS2k2OCClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	M1GwOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	MYDBdI9xfG:\|aYOgZZN{[Xl?		NVL0bGpOOjRiaILz	NYLKUGxDUW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDBNlc5OCClZXzsd{Bie3Onc4Pl[EBieyCrbnT1Z5Rqd25ib3[gVGFTWCClbHXheoFo\SCjdDDHTVUxKHSxIEXYS2k2OCClb37j[Y51emG2aX;uJIFnfGW{IEK0JIhzeyCkeTDX[ZN1\XKwIHLsc5R1cW6pIHHuZYx6e2m\|	M{DRO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{CxO\|Y4Lz5{M{OwNVc3PzxxYU6=
A2780	Ml\PSpVv[3Srb36gZZN{[Xl?		MlrlNlQhcHK\|	NYX6[2s{UW6qaXLpeIlwdiCxZjDDSGs6KGmwIHj1cYFvKEF{N{iwJINmdGy\|IHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJGhFVTJiYYSgS2k2OCC2bzC1XGdKPTBiY3;uZ4VvfHKjdHnvckBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91fGmwZzDhcoFtgXOrcx?=	NH\MfYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{OwNVc3Pyd-MkOzNFE4Pjd:L3G+
MT4	NU\RVYJxSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=			NF;ldGhCdnSrdnnyZYwh[WO2aY\peJkh[WejaX7zeEBJfW2jbjDpcY12dm:mZX\pZ4lmdmO7II\pdpV{KDFiTlygOE0{KGmwZnXjeIVlKGmwIF3UOEBk\WyuczDt[YF{fXKnZDDvckBl[XliNDDwc5N1KGmwZnXjeIlwdiCkeTDwNlQh[XO\|YYmsJGVEPTBiPTCwMlAyPSEQvF2u	MkjGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7MUS4NFQoRjJ3OUG0PFA1RC:jPh?=
MT4	Mm\2R5l1d3SxeHnjbZR6KGG\|c3H5			MoT3R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUXQ1KGOnbHzzMEBKSzVyIE2gNE4xPjdizszNMi=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
Sf9	M3fkcmZ2dmO2aX;uJIF{e2G7		NIHRSpIyPSCvaX7z	NFO3dm5KdmirYnn0bY9vKG:oIFPET\|Iw[3mlbHnuJGUyKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBqdnOnY4SgZ4VtdHNidYPpcochXWyrZ3j0R2ZHU06LVmTQVnRRWFCVUVfLMYFucWSnIIP1ZpN1emG2ZTDh[pRmeiBzNTDtbY5{KGK7IHH1eI9z[WSrb3fyZZBpgSxiSVO1NEA:KDBwMUOg{txONg>?	NFfnO489[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
A549	NH3xNmpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MYmzJIRigXN?	MX\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVAhRSByLkG0JO69VS5?	NIX0[ow9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
DU145	M1PuTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M1;NWlMh\GG7cx?=	NFTzfG9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFTVNVQ2KGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDTVmIhdWW2aH;kMEBIUTVyIE2gNE4yPSEQvF2u	NFPNc4E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
KB	Mlv6RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MX[zJIRigXN?	M4KyVmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiYX\0[ZIhOyCmYYnzJIJ6KFOUQjDt[ZRpd2RuIFfJOVAhRSByLkG2JO69VS5?	NGLiOVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUmxOFgxPCd-MkW5NVQ5ODR:L3G+
KBVIN	MnL2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFjhe4o{KGSjeYO=	NFi0OIhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvCWmlPKGOnbHzzJIFnfGW{IEOg[IF6eyCkeTDTVmIhdWW2aH;kMEBIUTVyIE2gNE4yQCEQvF2u	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTlzNEiwOEc,OjV7MUS4NFQ9N2F-
HCT116	MmrQRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWi3NkBpenN?	NX36UGNmSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JGNmdGy2aYTldk1IdG9icnXh[4VvfCCkYYPl[EBie3OjeTDpckBxemW\|ZX7j[UBw\iBzMDWg[oV1[WxiYn;2bY5mKHOncoXtMEBGSzVyIE2gNE4xOzRizszNMi=>	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6NUOwOUc,OjZ7OEWzNFU9N2F-
HCT116	NVrYSpIzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MXq3NkBpenN?	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscJRqfGW{LVfsc{Bz\WGpZX70JIJie2WmIHHzd4F6KGmwIIDy[ZNmdmOnIH;mJFAvPjJ3JTDm[ZRidCCkb4\pcoUhe2W{dX2sJGVEPTBiPTCwMlA2QSEQvF2u	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjl6NUOwOUc,OjZ7OEWzNFU9N2F-
Sf9	MnjXSpVv[3Srb36gZZN{[Xl?		MkXDNVAhdWmwcx?=	NUTp[GUxUW6qaXLpeIlwdiCxZjDoeY1idiCKaYO2MZRi\2enZDDDSGs6N2O7Y3zpckBVOSCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z7IHPlcIx{KHW\|aX7nJGdUXC2FVFSgZZMhe3Wkc4TyZZRmKGGodHXyJFExKG2rboOgbY4heHKnc3XuZ4Uhd2ZiW3fhcY1iNTN{UG3BWHAh[nliU1TTMXBCT0ViYX7hcJl{cXNuIFnDOVAhRSByLkCwNlUh\|ryPLh?=	M1Luc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MUexNFM3Lz5{N{G3NVA{PjxxYU6=
Sf21	M3fOXGZ2dmO2aX;uJIF{e2G7			NU[1[oVoUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDmeYxtKGynbnf0bEBENXSncn3pcoFtKEirc{[teIFo\2WmIFPET\|kw[3mlbHnuJHQyKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jJzIHnud4VkfCClZXzsd{B2e2mwZzDQSGt1cWSnIHHzJJN2[nO2cnH0[UwhUUN3MDC9JFAvODFzIN88UU4>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzF5MUCzOkc,OjdzN{GwN\|Y9N2F-
HeLa	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		NVq1dW14PzJiaILz	MmTpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVN[SClZXzsd{Bie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCFQ{WwJF0hOC5zMjFOwG0v	NHPhO3A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{G3NVA{Pid-MkexO\|ExOzZ:L3G+
sf21	NInscYtHfW6ldHnvckBie3OjeR?=			NETuSGtKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJIh2dWGwIF6teIVzdWmwYXygTIl{Pi22YXfn[YQhS0SNNj;OMZRmem2rbnHsJGdUXC22YXfn[YQh[3mlbHnuJGQ{KGW6cILld5Nm\CCrbjDz[lIyKGOnbHzzJJV{cW6pIHjpd5RwdmViSEGgd5Vje3S{YYTlMEBKSzVyIE2gNE4{QTVizszNMi=>	MkS4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdzN{GwN\|YoRjJ5MUexNFM3RC:jPh?=
Sf21	MUfGeY5kfGmxbjDhd5NigQ>?			MnLKTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDoeY1idiCodXzsJIxmdme2aDDDMZRmem2rbnHsJGhqezZvdHHn[4VlKEOGS{evZ5lkdGmwIFivUk11\XKvaX7hcEBIW1RvdHHn[4VlKE2DVEGg[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|IHnu[oVkfGWmIGPmNlEhcW6\|ZXP0JINmdGy\|IIXzbY5oKGOma{egd5Vje3S{YYTlJJBmeHSrZHWsJGlEPTBiPTCwMlUyPCEQvF2u	NXW4fGlCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkexO\|ExOzZpPkK3NVcyODN4PD;hQi=>
HepG2	M4LFVmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFrpTFM4OiCqcoO=	M{nPZmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcHRqfGW{LVfsc{Bie3OjeTygSWM2OCB;IECuNVQ3PCEQvF2u	NHH2OY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k4PSd-Mkm0NFc6PzV:L3G+
KOPN8	M2q3XWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWm3NkBpenN?	MmHqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCNT2DOPEBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR\|UxKD1iMD6xPVI3KM7:TT6=	NEf1UlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO\|k4PSd-Mkm0NFc6PzV:L3G+
SEM	NHXZOIdCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmS5O\|IhcHK\|	M4m0N2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iU1XNJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzUbZRmei2JbH:gZZN{[XluIFXDOVAhRSByLkKwOFMh\|ryPLh?=	M{T4WlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO\|k4PTxxYU6=
UOCB1	NXzkb3p[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX;1fXg6PzJiaILz	NXHRW2xOSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVU2NDOSClZXzsd{Bi\nSncjC3NkBpenNiYomgR4VtXGm2ZYKtS4xwKGG\|c3H5MEBGSzVyIE2gNE4zODh2IN88UU4>	MlrHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5O\|UoRjJ7NEC3PVc2RC:jPh?=
KOPN8	M1LFZWFxd3C2b4Ppd{Bie3OjeR?=	NGrzd40xNjVidV2=	NYTQSXBUOyC2bzCyOEBpenN?	MXvJcoR2[3Srb36gc4Yh[XCxcITvd4l{KGmwIHj1cYFvKEuRUF64JINmdGy\|IHHzd4V{e2WmIHHzJJVxemWpdXzheIlwdiCxZjDjcIVifmWmIGDBVnAhdGW4ZXygZZQhOC53IIXNJIFnfGW{IEOgeI8hOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	M324dFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO\|k4PTxxYU6=
KOPN8	Ml75RZBweHSxc3nzJIF{e2G7	MX2wMlUhfU1?	MmLUNUBpeg>?	Mme2TY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBxemVvdILlZZRm\CC5aYToJG5CSyCob4KgNUBpeiCjbnSgcYVie3W{ZXSgZYZ1\XJiMzD0c{AzPCCqcoOgZpkhX2W\|dHXyckBjdG:2IHHuZYx6e2m\|	M4HFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO\|k4PTxxYU6=

Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID

Western blot	CDK2 / CDK4 / Cyclin A / p21 / p27 / Rb ; p-ERK / ERK / p-p38 / p-4EBP1 / 4EBP1 / p-S6 ; p-RNAPII / p-eIF4E / Mnk1 ; Cleaved caspase-8 / Cleaved caspase-9 / Cleaved caspase-3	24572052 31193061
Growth inhibition assay	Cell viability	31193061

In vivo

Administration of Flavopiridol at 7.5 mg/kg for 7 days displays slight antitumor activity against P388 murine leukemia, resulting in %T/C value of 110, and active against the human A2780 ovarian carcinoma implanted sc in nude mice, producing 1.5 log cell kill (LCK). ^[5] Flavopiridol treatment at 1-2.5 mg/kg for 10 days significantly suppresses collagen-induced arthritis in mice in a dose-dependent manner, by inhibiting synovial hyperplasia and joint destruction, whereas serum concentrations of anti-collagen type II (CII) Abs and proliferative responses to CII are maintained. ^[6] In the p21-intact Hct116 xenografts in nude mice, administration of CPT-11 (100 mg/kg) followed by Flavopiridol (3 mg/kg) 7 and 16 hours later significantly inhibits tumor regression by 86% and 82%, respectively, displaying >2 fold inhibition compared with CPT-11 alone by 40 %. The combination produces ~30% complete response rate (CR) in contrast to CPT-11 alone where no CR is found. ^[7]

Protocol (from reference)

Kinase Assay: ^[1]	CDK kinase assay: For CDK1/cyclin B1 kinase assay, kinase reactions consist of 100 ng of baculovirus expressed GST-CDK1/cyclin B1 (human) complex, 1 μg histone HI, 0.2 μCi [γ-³³P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Tris, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 0.5 mM DTT). For CDK2/cyclin E kinase assay, kinase reactions consist of 5 ng of baculovirus expressed GST-CDK2/cyclin E (human) complex, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-³³P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 2 mM DTT). For CDK4/cyclin D1 kinase assay, kinase reactions consist of 150 ng of baculovirus expressed GST-CDK4/cyclin D1 (human), 280 ng of Stag-cyclin D1, 0.5 μg GST-RB fusion protein (amino acids 776-928 of retinoblastoma protein), 0.2 μCi [γ-³³P]ATP, 25 μM ATP in 50 μL kinase buffer (50 mM Hepes, pH 8.0, 10 mM MgCl₂, 1 mM EGTA, 2 mM DTT). Reactions are incubated for 45 minutes for CDK1 and CDK2, or 1 hour for CDK4 at 30 °C and stopped by the addition of cold trichloroacetic acid (TCA) to a final concentration 15%. TCA precipitates are collected onto GF/C unifilter plates using a Filtermate universal harvester and the filters are quantitated using a TopCount 96-well liquid scintillation counter. Flavopiridol is dissolved at 10 mM in dimethylformamide (DMF) and evaluated at six concentrations, each in triplicate. The final concentration of DMF in the assay = 2%. IC50 values are derived by nonlinear regression analysis and have a coefficient of variance = 16%. To assay Flavopiridol activity on CDK6, a filter-binding assay is established. The following are combined in the reaction mixture: 2 μL of CDK6 (0.7 mg/μL), 5 μL of histone H1 (6 mg/mL), 14 μL of kinase buffer (60 mM β-glycerophosphate, 30 mM p-nitrophenyl phosphate, 25 mM MOPS (pH 7.0), 5 mM EGTA, 15 mM MgCl₂, 1 mM DTT, 0.1 mM Na-vanadate), 3 μL of increasing concentrations of Flavopiridol diluted in 50% DMSO, and 6 μL of ³³P-ATP (1 mCi/mL) in nonradioactive ATP at 90 μM concentration (final concentration: 15 μM). The assay is initiated by the addition of ³³P-ATP. The reaction is incubated for 20 minutes at 30°C. A 25 μL aliquot of the supernatant is then spotted onto Whatman P81 phosphocellulose paper. Filters are washed 5 times with 1% phosphoric acid solution. Wet filters are counted in the presence of 1 mL of scintillation fluid. Cdk9 activity is measured using 50 nM of recombinant Cdk9/cyclin T in 50 mM HEPES pH 7.5, 10 mM MgCl₂, 1 mM DTT, 3 μM Na₃VO₄, 150 μM RNA polymerase CDT peptide and 80 μM ATP. Cdk7 assay is performed in the same buffer using 37 nM of purified kinase in the presence of 200 μM ATP and 10 μM myelin binding protein as a substrate. The potency of Flavopiridol toward CDK9 and CDK7 is determined using either a strong anion exchanger (Dowex 1-X8 resin, formate form)-based assay or a scintillation proximity assay. IC50 values are calculated from the dose-response curves.
Cell Research: ^[5]	Cell lines: MCF-7, LNCAP, PC3, HCT116, CACO-2, A549, HL60, K562 cells and et al. Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 72 hours Method: Cells are exposed to various concentrations of Flavopiridol for 72 hours at which time the tetrazolium dye, MTS in combination with phenazine methosulfate, is added. After 3 hours, the absorbency is measured at 492 nm, which is proportional to the number of viable cells. The results are expressed as IC50 values. For cell Cycle analysis, cells are fixed in paraformaldehyde and ethanol, washed, resuspended in staining solution of TdT enzyme and FITC-dUTP, washed, stained with PI following RNase treatment, and then analyzed by flow cytometry.
Animal Research: ^[5]	Animal Models: Female Balb/c×DBA/2J F1 mice inoculated ip with P388 ascites leukemic cells, and Balb/c nu/nu nude mice subcutaneous implanted with A2780, Br-cycE, or A431 cells Dosages: ~7.5 mg/kg/day Administration: Injection i.p.

References

+ Expand

Solubility (25°C)

In vitro


In vivo	Add solvents to the product individually and in order (Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+ddH2O For best results, use promptly after mixing. Click to purchase: PEG300	2.5mg/mL

Chemical Information

Molecular Weight	401.84
Formula	C₂₁H₂₀ClNO₅
CAS No.	146426-40-6
Storage	3 years	-20°C	powder
Storage	2 years	-80°C	in solvent
Smiles	CN1CCC(C(C1)O)C2=C(C=C(C3=C2OC(=CC3=O)C4=CC=CC=C4Cl)O)O

Download Flavopiridol (L86-8275) SDF

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

Clinical Trial Information

NCT Number	Recruitment	Interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03441555	Completed	Drug: Venetoclax\|Drug: Alvocidib	Acute Myeloid Leukemia (AML)	AbbVie\|Sumitomo Dainippon Pharma Oncology Inc	May 30 2018	Phase 1
NCT03298984	Completed	Drug: Alvocidib\|Drug: Cytarabine\|Drug: Daunorubicin	Acute Myeloid Leukemia	Sumitomo Dainippon Pharma Oncology Inc	September 25 2017	Phase 1

(data from https://clinicaltrials.gov, updated on 2022-01-17)

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):